Monthly Regulatory Roundup — June 2026

The FDA issued substantially equivalent determinations for seven devices across laser, LED, and radiofrequency platforms: Sanhe LEFIS Electronics' Intense Pulsed Light Therapy Device, Beijing Sano's LumiGlam Laser System, The Beauty Tech Group's CurrentBody Skin LED Multi Light Therapy Mask, Lumenis Be's MILAN System, F Care Systems' Veineo System, Eufoton's LASEmaR 1500, and Starmed's VIVA combo RF System. All are cleared for general and plastic surgery use.

What you must do:

• Verify any new devices you purchase carry valid 510(k) clearance documentation
• Update your device inventory and compliance files with clearance letters
• Review marketing claims against FDA-cleared indications only
• Confirm your staff training covers any new device parameters or safety protocols

Payless Compounders, LLC issued a Class II recall (ongoing status) for Semaglutide-Glycine-Cyanocobalamin Injectable in 2.5 mg, 5 mg, 1 MG/ML, and 0.5 mL vial presentations due to lack of assurance of sterility. This is a serious patient safety issue affecting any practice using this compounded formulation.

What you must do:

• Immediately audit your injectable inventory for any Payless Compounders products
• Quarantine affected stock and document lot numbers
• Notify patients who received injections from recalled lots
• Switch to verified alternative suppliers with documented sterility assurance and proper licensing
• Review your compounding pharmacy vetting process

The FDA's General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee has opened a public docket and called for comments on dermal fillers—signaling formal scrutiny of this category. Multiple Federal Register notices establish the public comment period and meeting schedule for this review.

What you must do:

• Monitor FDA.gov and the Federal Register for the official comment deadline
• Document your filler products' 510(k) clearances and post-market data
• Prepare to submit adverse event reports and clinical outcome data if requested
• Consider submitting comments on behalf of your practice or through industry associations
• Ensure all filler marketing materials align with cleared indications only

Use this checklist to ensure your practice stays compliant across all three regulatory developments:

• Verify all seven newly cleared devices against your current and planned purchases
• Cross-reference your injectable suppliers against the Payless Compounders recall list
• Confirm staff training on any new device protocols before clinical use
• Document all patient notifications related to the semaglutide recall
• Establish a system to track FDA advisory committee activity on fillers
• Review your compounding pharmacy contracts for sterility assurance language
• Audit your adverse event reporting process

The FDA's formal advisory committee review of dermal fillers is not a ban or imminent recall, but it signals the agency is re-examining this category's safety profile and clinical evidence. This is standard regulatory practice and typically precedes guidance updates or labeling changes.

Prepare now by:

• Maintaining detailed records of filler brand, lot number, and patient outcomes
• Training staff on proper injection technique and adverse event recognition
• Staying current on published safety data and post-market surveillance reports
• Engaging with industry groups monitoring the advisory committee process
• Reviewing your informed consent forms to ensure they reflect current FDA guidance